BR112017010101A2 - uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central - Google Patents
uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso centralInfo
- Publication number
- BR112017010101A2 BR112017010101A2 BR112017010101A BR112017010101A BR112017010101A2 BR 112017010101 A2 BR112017010101 A2 BR 112017010101A2 BR 112017010101 A BR112017010101 A BR 112017010101A BR 112017010101 A BR112017010101 A BR 112017010101A BR 112017010101 A2 BR112017010101 A2 BR 112017010101A2
- Authority
- BR
- Brazil
- Prior art keywords
- central nervous
- checkpoint inhibitors
- neoplasms
- nervous system
- immune system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Abstract
a presente invenção refere-se a um método para tratar glioma em um indivíduo que compreende administrar ao indivíduo um anticorpo anti-morte programada-1 (pd-1). em algumas modalidades, esta invenção refere-se a métodos para tratar glioma em um indivíduo que compreendem administrar ao indivíduo uma combinação de um agente anticâncer que é um anticorpo anti-morte programada-1 (pd-1) e outro agente anticâncer tal como um anticorpo antiantígeno 4 associado ao linfócito t citotóxico (ctla-4).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462092783P | 2014-12-16 | 2014-12-16 | |
US201562261130P | 2015-11-30 | 2015-11-30 | |
PCT/US2015/066177 WO2016100561A2 (en) | 2014-12-16 | 2015-12-16 | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017010101A2 true BR112017010101A2 (pt) | 2018-01-02 |
Family
ID=56127849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017010101A BR112017010101A2 (pt) | 2014-12-16 | 2015-12-16 | uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central |
Country Status (9)
Country | Link |
---|---|
US (2) | US20180133313A1 (pt) |
EP (1) | EP3233123A4 (pt) |
JP (2) | JP2018500332A (pt) |
CN (1) | CN106999590A (pt) |
BR (1) | BR112017010101A2 (pt) |
CA (1) | CA2969338A1 (pt) |
MX (1) | MX2017007390A (pt) |
RU (1) | RU2726996C1 (pt) |
WO (1) | WO2016100561A2 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03527B (me) | 2013-12-12 | 2020-04-20 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antitijelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primjena |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
SG10201913500TA (en) | 2015-05-29 | 2020-03-30 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
BR112018002824A2 (pt) | 2015-08-11 | 2018-11-06 | Open Monoclonal Tech Inc | anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo |
PE20181322A1 (es) | 2015-09-01 | 2018-08-14 | Agenus Inc | Anticuerpo anti-pd1 y sus metodos de uso |
WO2017176925A1 (en) | 2016-04-05 | 2017-10-12 | Bristol-Myers Squibb Company | Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
GB201618291D0 (en) * | 2016-10-28 | 2016-12-14 | Bergen Teknologioverf�Ring As | Novel immunotherapeutic treatments for tumours |
BR112019011410A2 (pt) | 2016-12-05 | 2019-10-22 | G1 Therapeutics Inc | métodos para tratar um paciente tendo câncer, para aumentar uma população da célula efetora imune pró-inflamatória, para aumentar o nível de ativação de célula t, para reduzir a população de células t reguladoras, para inibir a função imunossupressora das células t reguladoras, para o realce de longa duração da geração das células t de memória específicas de tumor e para proteger as células imunológicas intratumorais da quimioterapia. |
WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
DE102017119868B4 (de) * | 2017-07-12 | 2021-05-27 | Bruker Daltonik Gmbh | Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie |
JP7159007B2 (ja) * | 2017-11-01 | 2022-10-24 | 小野薬品工業株式会社 | 脳腫瘍の治療のための医薬 |
CN111971306A (zh) * | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
SG11202011651SA (en) * | 2018-05-31 | 2020-12-30 | Ono Pharmaceutical Co | Biomarkers for determining the effectiveness of immune checkpoint inhibitors |
EP3941467A4 (en) * | 2019-03-19 | 2022-12-21 | ChemoCentryx, Inc. | COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR-2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR |
CN114980930A (zh) * | 2019-12-27 | 2022-08-30 | 志瑞亚新药工业株式会社 | 癌症治疗方法及药物 |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
US20230365690A1 (en) * | 2020-08-07 | 2023-11-16 | Northwestern University | Methods of treating malignant glioblastoma |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011002252A (es) * | 2008-08-25 | 2011-06-24 | Amplimmune Inc | Composiciones de antagonistas del pd-1 y metodos de uso. |
AU2009296392B2 (en) * | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
RU2402360C1 (ru) * | 2009-07-08 | 2010-10-27 | Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) | Способ лечения злокачественной глиомы головного мозга |
CN102178676B (zh) * | 2011-04-29 | 2012-07-25 | 山东大学 | 一种治疗脑胶质瘤的药物组合物 |
WO2012177624A2 (en) * | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
SG11201407190TA (en) * | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
-
2015
- 2015-12-16 MX MX2017007390A patent/MX2017007390A/es unknown
- 2015-12-16 BR BR112017010101A patent/BR112017010101A2/pt not_active Application Discontinuation
- 2015-12-16 EP EP15871017.8A patent/EP3233123A4/en active Pending
- 2015-12-16 US US15/536,785 patent/US20180133313A1/en not_active Abandoned
- 2015-12-16 WO PCT/US2015/066177 patent/WO2016100561A2/en active Application Filing
- 2015-12-16 CA CA2969338A patent/CA2969338A1/en not_active Abandoned
- 2015-12-16 CN CN201580069022.6A patent/CN106999590A/zh active Pending
- 2015-12-16 JP JP2017532140A patent/JP2018500332A/ja active Pending
- 2015-12-16 RU RU2017125052A patent/RU2726996C1/ru active
-
2020
- 2020-07-20 US US16/933,547 patent/US20210000953A1/en not_active Abandoned
-
2021
- 2021-08-12 JP JP2021131637A patent/JP2021181482A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2969338A1 (en) | 2016-06-23 |
JP2021181482A (ja) | 2021-11-25 |
WO2016100561A2 (en) | 2016-06-23 |
EP3233123A4 (en) | 2018-05-09 |
JP2018500332A (ja) | 2018-01-11 |
WO2016100561A3 (en) | 2016-08-18 |
MX2017007390A (es) | 2017-11-06 |
RU2726996C1 (ru) | 2020-07-17 |
US20180133313A1 (en) | 2018-05-17 |
EP3233123A2 (en) | 2017-10-25 |
US20210000953A1 (en) | 2021-01-07 |
CN106999590A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017010101A2 (pt) | uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central | |
CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
CL2018000744A1 (es) | Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso. | |
CO2017010618A2 (es) | Anticuerpos contra icos | |
CL2017001408A1 (es) | Anticuerpos anti-cd79b y métodos de uso | |
MX2022001878A (es) | Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso. | |
BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
BR112017017927A2 (pt) | receptores quiméricos de antígenos anti-dll3 e métodos de uso | |
BR112017008914A2 (pt) | método para tratar câncer, composição e uso da composição | |
DOP2019000165A (es) | Anticuerpos anti-ox40 y sus usos | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
CL2016000341A1 (es) | Métodos para tratar la miositis por cuerpos de inclusión esporádica | |
BR112016014952A2 (pt) | Inibição direcionada de tgfbeta | |
CO2018012699A2 (es) | Anticuerpos anti-cd40 y sus usos | |
BR112016017256A2 (pt) | combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer | |
CL2019000230A1 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos. | |
BR112017000497A2 (pt) | ?anticorpos anti pd-l1 e usos de diagnóstico dos mesmos? | |
BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
BR112016010271A2 (pt) | Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação | |
CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
CL2016002257A1 (es) | Anticuerpos anti-mcam y métodos de uso asociados | |
BR112016029860A2 (pt) | conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos | |
ECSP17031725A (es) | Receptores quiméricos de anitígeno anti-clon y métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |